Quince Therapeutics

Quince Therapeutics, formely known as Cortexyme, focuses on precision therapeutics targeting debilitating and rare diseases.

failure crash no fail rocket cancelled end
Pharma

Quince explores options after ph. 3 rare disease flop

Quince’s stock price plummeted more than 90% on the phase 3 failure, and the company now intends to "preserve cash and explore available options."
Angus Liu Jan 30, 2026 10:44am